免疫检查点抑制剂联合化疗用于子宫内膜癌一线治疗:仍是微卫星的时代吗
本Meta分析纳入随机临床试验,比较免疫检查点抑制剂(ICI)联合化疗与化疗联合安慰剂一线治疗晚期子宫内膜癌的疗效与安全性,共1303例患者。结果显示联合ICI显著改善错配修复缺陷(dMMR)和错配修复完整(pMMR)患者的无进展生存期(PFS),但≥3级不良事件风险增加。
要点
- 在dMMR患者中,ICI联合化疗较对照显著改善PFS(HR 0.29;95%CI 0.20-0.42;p<0.00001)。
- 在pMMR患者中,ICI联合化疗较对照显著改善PFS(HR 0.64;95%CI 0.46-0.90;p=0.01)。
- ICI联合化疗组≥3级不良事件风险较对照组增加(RR 1.22;95%CI 1.11-1.34;p<0.0001)。
核心结论
- 在晚期子宫内膜癌一线治疗中,化疗联合ICI较化疗联合安慰剂显著改善PFS,且获益与MMR状态无关。
研究设计与样本
- 研究设计为随机临床试验的Meta分析,纳入实验组接受ICI联合化疗、对照组接受化疗联合安慰剂的晚期子宫内膜癌患者,共1303例接受治疗。
主要发现
- dMMR患者中,ICI联合化疗较对照组显著改善PFS(HR 0.29;95%CI 0.20-0.42;p<0.00001)。
- pMMR患者中,ICI联合化疗较对照组显著改善PFS(HR 0.64;95%CI 0.46-0.90;p=0.01)。
- 所有级别不良事件在两组间无显著差异(RR 1.00;p=0.98)。
- ICI联合化疗组≥3级不良事件风险较对照组增加(RR 1.22;95%CI 1.11-1.34;p<0.0001)。
临床怎么用
- 原文结论为在晚期子宫内膜癌一线治疗中化疗联合ICI较化疗联合安慰剂显著改善PFS,且不论MMR状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The combination of immune checkpoint inhibitors (ICIs) plus chemotherapy is currently being tested as the first-line treatment of advanced endometrial. We aimed to evaluate the efficacy and safety of this combination. DESIGN: We performed a meta-analysis of randomized clinical trials. POPULATION AND SETTING: Patients with advanced endometrial carcinoma receiving ICIs plus chemotherapy in the experimental arm, compared with chemotherapy plus placebo in the control arm, were included. METHODS AND OUTCOMES: We evaluated the progression-free survival (PFS) as an efficacy outcome and the number and grades of adverse events (AEs) for safety. Hazard ratios (HR) for PFS and risk ratios (RR) for AEs, with 95% confidence intervals (CI), were calculated. RESULTS: 1303 patients were treated in the included studies. Adding ICIs to chemotherapy significantly improved PFS in mismatch repair deficient (dMMR-HR 0.29; 95% CI, 0.20-0.42; p < 0.00001) and in mismatch repair proficient (pMMR-HR 0.64; 95% CI, 0.46-0.90; p = 0.01) patients. No difference emerged for all-grades AEs (RR 1.00; p = 0.98), but the risk of ≥G3 AEs was increased in the ICIs + chemotherapy group (RR 1.22; 95% CI, 1.11-1.34; p < 0.0001). CONCLUSIONS: Adding ICIs to chemotherapy significantly improves PFS in first-line endometrial cancer, regardless of MMR status.
引用
- Maiorano MFP, Messina C, Maiello E, et al. Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites? BJOG. 2024. PMID: 38164107. doi:10.1111/1471-0528.17749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。